| Bioactivity | Kayexalate, a cation-exchange resin, is an orally active plasma potassium inhibitor. Kayexalate can be used in the research of hyperkalemia[1][2]. |
| In Vivo | Propiomazine (5 g/kg, oral gavage) lowers serum Li concentrations in CD-1 mice[2].Propiomazine (5 g/kg, oral gavage) reduces serum K concentrations in CD-1 mice[3]. Animal Model: |
| Name | Kayexalate |
| CAS | 37349-16-9 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Harel Z, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013 Mar;126(3):264.e9-24. [2]. J G Linakis, et al. Enhancement of lithium elimination by multiple-dose sodium polystyrene sulfonate. Acad Emerg Med. 1997 Mar;4(3):175-8. [3]. Linakis JG, et al. Sodium polystyrene sulfonate treatment for lithium toxicity: effects on serum potassium concentrations. Acad Emerg Med. 1996 Apr;3(4):333-7. |